Abstract:Introduction: Today, rapid technical and clinical developments result in an increasing number of treatment options for oncological diseases. Thus, decision support systems are needed to offer the right treatment to the right patient. Imaging biomarkers hold great promise in patient-individual treatment guidance. Routinely performed for diagnosis and staging, imaging datasets are expected to hold more information than used in the clinical practice. Radiomics describes the extraction of a large number of meaningful quantitative features from medical images, such as computed tomography (CT) and positron emission tomography (PET). Due to the non-invasive nature and ability to capture 3D image-based heterogeneity, radiomic features are potential surrogate markers of the cancer phenotype. Several radiomic studies are published per day, owing to encouraging results of many radiomics-based patient outcome models. Despite this comparably large number of studies, radiomics is mainly studied in proof of principle concept. Hence, a translation of radiomics from a hot topic research field into an essential clinical decision-making tool is lacking, but of high clinical interest. Evidence acquisition: Herein, we present a literature review addressing the clinical evidence of CT and PET radiomics. An extensive literature review was conducted in PubMed, including papers on robustness and clinical applications. Evidence synthesis: We summarize image-modality related influences on the robustness of radiomic features and provide an overview of clinical evidence reported in the literature. Today, more evidence has been provided for CT imaging, however, PET imaging offers the promise of direct imaging of biological processes and functions. We provide a summary of future research directions, which needs to be addressed in order to successfully introduce radiomics into clinical medicine. In comparison to CT, more focus should be directed towards harmonization of PET acquisition and reconstruction protocols, which is important for transferable modelling. Conclusions: Both CT and PET radiomics are promising pre-treatment and intra-treatment biomarkers for outcome prediction. Most studies are performed in retrospective setting, however their validation in prospective data collections is ongoing.

Research progress of PET related radiomics in tumor prognosis

PET radiomics in lung cancer: advances and translational challenges

Current status and prospect of PET-related imaging radiomics in lung cancer

[Advances on Correlation of PET-CT Findings with Breast Cancer Molecular Subtypes, Treatment Response and Prognosis].

Positron Emission Tomography/computerized Tomography for Tumor Response Assessment-a Review of Clinical Practices and Radiomics Studies.

Prospect and Status of PET Radiopharmaceuticals in Oncology

Recent advances of PET?CT for lung cancer:a review of radiomics studies

Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer

Medical imaging in tumor precision medicine: opportunities and challenges

Radiomics in Antineoplastic Agents Development: Application and Challenge in Response Evaluation.

The application progress of PET-MRI new technique

The progress of PET/MRI in clinical management of patients with pancreatic malignant lesions

Progress and Prospects of PET/MRI Imaging

PET Hypoxia Imaging and Progress of Enhancing Radio-Sensitivity in Hypoxic Tumor

CT radiomics and PET radiomics: ready for clinical implementation?

[Progress in Precision Medicine of Radiomics in Abdominal Tumors Practice].

Role of Radiomics-Based Baseline PET/CT Imaging in Lymphoma: Diagnosis, Prognosis, and Response Assessment

Progress of PET/MRI techniques

Prospect of Study and Application on PET Receptor Imaging

PET/CT radiomics in breast cancer: Mind the step

The Applications of Radiomics in Precision Diagnosis and Treatment of Oncology: Opportunities and Challenges